l -Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits
Science Advances · 07.11.2025 · 11 (45)
DOI: 10.1126/sciadv.adt4123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 07.11.2025. Verfasst von Jacopo Di Lucente und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and MIND Institute, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Fucose, Synapses, Neurotransmitter Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Fucosylation, a major glycan modification, has been shown to influence neuronal and microglial mechanisms, but whether unconjugated free l -fucose can affect brain function is unknown. l -Fucose can be transported into cells and metabolized by fucokinase (FCSK) via the poorly understood salvage pathway. Using mouse hippocampal slices, we showed that l -fucose enhanced excitatory neurotransmission and long-term potentiation (LTP) through regulation of presynaptic release. Such effects required l -fucose be metabolized through the FCSK-driven salvage pathway, suggesting a metabolic-signaling mechanism. Human Alzheimer’s disease (AD) and 5xFAD mouse brains showed signs of fucose hypometabolism with impaired l -fucose signaling. Such abnormalities were corrected by exogenous l -fucose, exemplified by rectification of LTP deficits in 5xFAD hippocampus. A dietary l -fucose supplement, which increased cerebral free l -fucose levels and up-regulated FCSK to drive the salvage pathway, mitigated synaptic and behavioral deficits of 5xFAD mice. Our data suggest an unrecognized neuromodulatory function of free l -fucose and reveals its therapeutic potential for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and MIND Institute, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA.
- MIND Institute, University of California Davis Medical Center, 2805 50th Street, Sacramento, CA 95817, USA.
- Department of Chemistry, University of California, Davis, CA 95616, USA.
- Alzheimer's Disease Research Center, University of California Davis Medical Center, 4860 Y Street, Suite 3900, Sacramento, CA 95817, USA.
ORCID-Profile: Jacopo Di Lucente, Yuanyuan Bai, Elizabeth K Neumann, Xi Chen, Carlito B Lebrilla, Izumi Maezawa, Lee-Way Jin
Förderung
- NIA NIH HHS
Zitieren
APA
Di Lucente, J., Tena, J., Bai, Y., Shafer, C. C., Mendiola, U. R., Neumann, E. K., Chen, X., Lebrilla, C. B., Maezawa, I., & Jin, L. W. (2025). l -Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits. Science Advances, 11(45). https://doi.org/10.1126/sciadv.adt4123
Vancouver
Di Lucente J, Tena J, Bai Y, Shafer CC, Mendiola UR, Neumann EK, et al. l -Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits. Science Advances. 2025;11(45). doi:10.1126/sciadv.adt4123
BibTeX
@article{DiLucente2025,
author = {Di Lucente, Jacopo and Tena, Jennyfer and Bai, Yuanyuan and Shafer, Catelynn C and Mendiola, Ulises Ruiz and Neumann, Elizabeth K and Chen, Xi and Lebrilla, Carlito B and Maezawa, Izumi and Jin, Lee-Way},
title = {l -Fucose is a candidate monosaccharide neuromodulator and mitigates Alzheimer’s synaptic deficits},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {45},
doi = {10.1126/sciadv.adt4123}
}
EUVIMED